Indolent B-Cell Non-Hodgkin Lymphoma — Variants & evidence

Indolent B-Cell Non-Hodgkin Lymphoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items (3 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MYD88 L265P2
Ibrutinib	Lymphoplasmacytic Lymphoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID986 A prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with M… (full text at CIViC) PMID 25853747 · Treon et al., 2015 · Open in CIViC	civic
IMG-2005-5 + IRAK-1/4 InhibitorSubstitutes	Lymphoplasmacytic Lymphoma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1641 In a study of 30 patients with Waldenström’s macroglobulinemia, 87% had MYD88(L265P) mutations. Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization… (full text at CIViC) PMID 22931316 · Treon et al., 2012 · Open in CIViC	civic
TP53 V143A1
(diagnostic)	Lymphoplasmacytic Lymphoma	Diagnostic	C	Supports N/A	2	submitted	EID2891 A 73 y.o. male with Waldenström's Macroglobulinemia, a rare type of non-Hodgkin's lymphoma, donated bone marrow upon cancer recurrence to establish the cell line MWCL1. The bone marrow was initially … (full text at CIViC) PMID 21415268 · Hodge et al., 2011 · Open in CIViC	civic

Data updated 14 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.